Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.

Dosani T, Covut F, Pinto R, Kim BG, Ali N, Beck R, Maitta R, Downes K, Fox R, Reese J, de Lima M, Malek E.

Leuk Lymphoma. 2019 Mar 7:1-8. doi: 10.1080/10428194.2019.1573367. [Epub ahead of print]

PMID:
30845862
2.

Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.

Bhutani D, Zonder J, Valent J, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Lum L, Ratanatharathorn V, Uberti J, Abidi MH.

Support Care Cancer. 2013 Sep;21(9):2437-42. doi: 10.1007/s00520-013-1808-5. Epub 2013 Apr 17.

3.

Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.

Kumar R, Kapoor R, Asthana B, Singh J, Verma T, Chilaka R, Singh NK, Sharma A, Das S, Nair V.

Indian J Hematol Blood Transfus. 2017 Dec;33(4):463-469. doi: 10.1007/s12288-017-0798-8. Epub 2017 Mar 3.

4.

Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.

Yuan S, Palmer JM, Tsai NC, Dagis A, Nademanee A, Wang S.

Hematol Oncol. 2017 Sep;35(3):281-287. doi: 10.1002/hon.2286. Epub 2016 Feb 29.

PMID:
26928577
5.

Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.

Salhotra A, Shan Y, Tsai NC, Sanchez JF, Aldoss I, Ali H, Paris T, Spielberger R, Cao TM, Nademanee A, Forman SJ, Chen R.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1264-1268. doi: 10.1016/j.bbmt.2017.04.011. Epub 2017 Apr 18.

6.

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA.

Leukemia. 2007 Sep;21(9):2035-42. Epub 2007 Jun 21.

PMID:
17581613
7.

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.

Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.

J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.

PMID:
23765597
8.

Increased plasma EPO and MIP-1 alpha are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts.

Labonté L, Li Y, Yang L, Gillingham A, Halpenny M, Giulivi A, Sills T, Evans K, Zanke B, Allan DS.

Exp Hematol. 2009 Jun;37(6):673-8. doi: 10.1016/j.exphem.2009.02.010.

PMID:
19463769
9.

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.

Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT).

Int J Hematol. 2019 Jan;109(1):107-114. doi: 10.1007/s12185-018-2543-y. Epub 2018 Oct 4. Erratum in: Int J Hematol. 2018 Nov 7;:.

PMID:
30284685
10.

Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.

Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.

Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31.

PMID:
25130876
11.
12.

Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors.

Allan DS, Dubé P, Roy J, Busque L, Roy DC.

Biol Blood Marrow Transplant. 2007 Apr;13(4):433-9. Epub 2007 Feb 15.

13.

Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.

Yuan S, Nademanee A, Kaniewski M, Palmer J, Shayani S, Wang S.

Transfusion. 2014 Aug;54(8):2015-21. doi: 10.1111/trf.12594. Epub 2014 Mar 24.

PMID:
24660786
14.

Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.

Moreb JS, Byrne M, Shugarman I, Zou F, Xiong S, May WS, Norkin M, Hiemenz J, Brown R, Cogle C, Wingard JR, Hsu JW.

J Clin Apher. 2018 Feb;33(1):29-37. doi: 10.1002/jca.21556. Epub 2017 May 29.

PMID:
28556233
15.

Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.

Teusink A, Pinkard S, Davies S, Mueller M, Jodele S.

Transfusion. 2016 Jun;56(6):1402-5. doi: 10.1111/trf.13599. Epub 2016 Apr 15.

PMID:
27079854
16.

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma.

Agarwal R, Abidi MH.

Hematol Rep. 2012 Nov 19;4(4):e26. doi: 10.4081/hr.2012.e26. Epub 2012 Dec 6.

17.

Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2065-2069. doi: 10.1016/j.bbmt.2017.07.023. Epub 2017 Aug 7.

18.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

19.
20.

Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.

Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K.

Amyloid. 2014 Sep;21(3):149-53. doi: 10.3109/13506129.2014.900486. Epub 2014 Apr 29.

PMID:
24779777

Supplemental Content

Support Center